GLP-1 Medications: What You Need to Know

Key Takeaways

• GLP-1 receptor agonists have been associated with reductions in body weight and improvements in dietary quality, including changes in food cravings, according to the CRAVE study (PMID 42440974).
• A multicenter U.S. cohort study found tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared to certain other treatments (PMID 42460324).
• Research comparing GLP-1 receptor agonists to bariatric surgery and other weight-loss drugs suggests a potentially favorable cancer risk profile, though more long-term data are needed (PMID 42447648).
• Genetic differences in GLP-1 and GIP receptors may influence how individuals respond to incretin therapies, pointing toward a future of more personalized treatment (PMID 42487666).
• Compounded GLP-1 products remain available in some markets even after drug shortage designations end, raising quality and safety questions consumers should discuss with their provider (PMID 42467450).

What Are GLP-1 Medications and How Do They Work?

GLP-1 medications are a class of drugs that mimic a natural gut hormone to help control blood sugar, reduce appetite, and support weight loss. They work by activating specific receptors in the body—think of a receptor as a lock and the medication as a key—triggering effects that change how you experience hunger, process food, and store energy.

Here's what happens in your body when you take a GLP-1 medication:

• Slowing digestion. GLP-1 receptor agonists (the full name for this drug class; "agonist" means a substance that activates a receptor) slow how quickly your stomach empties food into your intestines. This helps you feel full longer after eating, as noted in the CRAVE study.

• Reducing appetite and cravings. The same CRAVE study found that people using GLP-1 receptor agonists reported meaningful changes in food cravings and dietary intake—the medication appears to quiet mental preoccupation with food, not just physical hunger.

• Regulating blood sugar. These medications prompt the pancreas to release insulin when blood sugar rises (such as after a meal) and reduce glucagon release, a hormone that raises blood sugar. The result is steadier glucose levels throughout the day, a mechanism described in this older-adults review.

• Signaling the brain. GLP-1 receptors exist in the brain as well as the gut. When activated, they reduce the reward-driven urge to eat—part of why many people on these medications report thinking about food less often.

The most commonly used GLP-1 medications include semaglutide (brand names Ozempic and Wegovy) and liraglutide (Saxenda). A newer option, tirzepatide (Mounjaro, Zepbound), activates two receptors—GLP-1 and GIP—and has shown strong results in network meta-analyses comparing weight-loss medications.

Individual responses vary. Research suggests that genetic differences in how your body's receptors are structured may influence how well a particular medication works for you, according to this review on incretin therapy personalization. This is why your experience may differ from someone else's—and why working closely with your prescriber matters.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

How Do GLP-1 Medications Affect Weight, Cravings, and Diet?

GLP-1 medications work by mimicking a natural gut hormone that signals fullness, slows stomach emptying, and reduces cravings — effects that together make it easier to eat less without feeling deprived. Research shows these changes extend beyond simple appetite suppression and reshape how you relate to food.

How the hunger signal works

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after you eat. GLP-1 receptor agonists copy that signal and sustain it longer than your body naturally would. The result: your brain receives a prolonged "I've had enough" message. A systematic review and network meta-analysis found that GLP-1 receptor agonists produced meaningful reductions in body weight compared with placebo in adults with overweight or obesity, making them among the most effective non-surgical weight-loss tools currently available.

What happens to cravings and food choices

The effects extend beyond portion control. According to the CRAVE study, people using GLP-1 receptor agonists experienced:

• Reduced food cravings — particularly for high-fat and high-sugar foods
• Improved dietary quality — participants shifted toward more nutrient-dense choices over time
• Changes in body composition — reductions in fat mass alongside overall weight loss
• Lower total caloric intake — without consciously restricting calories

This matters for anyone combining these medications with fasting: the medication may make your eating window more manageable because the pull toward calorie-dense foods genuinely weakens.

Slower stomach emptying — a double-edged effect

GLP-1 medications slow gastric emptying (the rate food moves from your stomach into your intestines). This extends fullness after meals, supporting both weight loss and fasting adherence. However, special considerations Research notes this effect can also contribute to nausea, especially early in treatment or during dose increases — something to consider when planning your eating window.

Individual response varies

Not everyone experiences the same degree of appetite change. Research on incretin therapy personalization suggests that genetic differences in GLP-1 receptors may influence how strongly a person responds to these medications — one reason outcomes differ from person to person even on the same dose.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or dietary practice.

What Does Research Say About Cardiovascular and Cancer Risks?

Early Research suggests GLP-1 medications may offer meaningful cardiovascular benefits and are unlikely to raise cancer risk — and may actually lower it for certain obesity-related cancers. Here is what the current evidence shows, and where important questions remain.

---

On cardiovascular and clot-related risks:

• Blood clot protection: A large U.S. multicenter study found that tirzepatide (a dual GIP/GLP-1 receptor agonist) was associated with a reduced risk of pulmonary embolism (blood clot in the lungs) and deep vein thrombosis (clot in a deep vein, usually the leg). This finding is meaningful for people with obesity, who already carry elevated clot risk. (multicenter U.S. cohort study)

• Broader weight-loss comparison: A systematic review and network meta-analysis found that GLP-1 class medications compare favorably to other weight-loss drugs on several health outcomes, including cardiometabolic markers. (systematic review and meta-analysis)

---

On cancer risk:

• GLP-1s do not appear to raise cancer risk in people using them for obesity. When researchers compared GLP-1 receptor agonists to bariatric surgery and other weight-loss drugs, GLP-1 medications were associated with reduced risk of several obesity-related cancers — cancers linked to excess body weight over time. (cancer risk comparison study)

• This matters because obesity itself is a known risk factor for more than a dozen cancer types. Sustained weight loss — whether from surgery, medication, or lifestyle change — appears to lower that underlying risk. (cancer risk comparison study)

---

What we don't yet know:

Most studies to date are observational, meaning researchers tracked outcomes in real patients rather than conducting a controlled experiment. This makes it difficult to establish whether GLP-1 medications caused these benefits or whether healthier patients were more likely to use them. Longer-term randomized trials are still needed.

---

The bottom line: Early signals on cardiovascular and cancer outcomes are encouraging, but no medication — including GLP-1s — guarantees protection. Pairing medication with consistent fasting, whole-food eating, and movement provides the strongest foundation.

⚠️ This content is for general informational purposes only and is not medical advice. Talk with your healthcare provider before making any changes to your medication, diet, or health routine.

Are GLP-1 Medications Safe for Older Adults?

GLP-1 medications can be used safely by many older adults. Still, they require closer monitoring and dose adjustments than in younger people because aging changes how the body handles both the drug and its effects.

Why age matters with GLP-1 medications

As people age, several physiological changes occur: muscle mass naturally decreases, kidney function declines, appetite is often already reduced, and fall risk increases. Each of these factors can interact with how a GLP-1 medication works in the body. According to a clinical review on GLP-1 use in older adults (source), these age-related changes mean that standard dosing and monitoring protocols designed for middle-aged adults may not apply directly to people over 65.

Specific risks to know about

• Muscle loss (sarcopenia): GLP-1 medications significantly reduce appetite. In older adults, reduced food intake can accelerate the natural loss of muscle that accompanies aging. The clinical review identifies this as a key concern, noting that preserving muscle through adequate protein intake and resistance exercise is especially important for older users.

• Malnutrition and dehydration: Reduced hunger combined with nausea—a common side effect—can make it harder for older adults to meet basic nutritional needs. Research from the CRAVE study confirmed that GLP-1 therapy meaningfully changes food intake and dietary patterns, underscoring why nutrition monitoring becomes more critical with age.

• Fall risk: Weight loss and reduced calorie intake can contribute to weakness or dizziness, raising fall risk—a serious concern for older adults. The clinical review identifies fall prevention as part of a safe treatment plan for this age group.

• Kidney function: Because kidney filtering slows with age, some medications clear the body more slowly. The clinical review recommends assessing kidney function before and during GLP-1 therapy in older patients.

What this means in practice

Older adults are not automatically excluded from GLP-1 therapy, but treatment should be individualized. Starting at a lower dose, titrating more slowly, and scheduling regular check-ins with a healthcare provider are reasonable steps. Pairing the medication with structured resistance exercise and protein-focused eating can help protect muscle mass.

If you are over 65 and considering or already using a GLP-1 medication alongside fasting, bring this section to your next appointment and ask your provider to review your kidney function, muscle health, and fall risk as part of your treatment plan.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or health program.

What Should You Know About Compounded GLP-1 Products?

Compounded GLP-1 products are copies of brand-name medications mixed by specialty pharmacies. While they may be more affordable or accessible, they carry real quality and safety uncertainties that every user should understand before choosing one.

What "compounded" means

A compounded medication is one that a pharmacy mixes from raw ingredients, outside the standard drug-manufacturing process. Compounded versions of GLP-1 medications—such as semaglutide or tirzepatide—are not FDA-approved, meaning they haven't undergone the same testing for purity, potency, or sterility as brand-name products.

Why people use them

Compounded GLP-1 products became widely available during brand-name shortages. Research found that compounded GLP-1 use was documented across patient records in ways standard prescription data often missed, suggesting use is more common than official numbers show. A separate study examining two high-demand states found compounded GLP-1 products widely available even after shortages eased, pointing to ongoing demand driven largely by cost and access.

Key risks

• Uncertain dosing: Compounded products may not deliver the same dose as the brand-name version. Underdosing reduces effectiveness; overdosing increases the risk of nausea, vomiting, or low blood sugar.
• Uncontrolled ingredients: Some compounded versions include added substances (like B vitamins) that haven't been tested in combination with GLP-1 medications.
• No FDA oversight: Unlike brand-name drugs, compounded medications aren't reviewed for consistency between batches.
• Injection safety: Most GLP-1 medications are injected. Improperly compounded injectables carry contamination risk.

If you're also fasting

Combining a GLP-1 medication with intermittent fasting or calorie restriction already significantly reduces appetite and food intake. Research from the CRAVE study found that GLP-1 therapy meaningfully changes food cravings and dietary intake. An inconsistent dose from a compounded product could make it harder to manage energy levels, hydration, and nutrition during fasting windows.

Bottom line

If cost or access is pushing you toward a compounded product, that's a real concern—but discuss it with your prescribing provider. They can help you weigh the tradeoffs and explore assistance programs for brand-name options.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any changes to your medication or health routine.

Could Your Genes Affect How Well GLP-1 Medications Work for You?

Yes, your genes can influence how well GLP-1 medications work for you. Research shows that natural variations in genes controlling GLP-1 and GIP receptors may affect weight loss and blood sugar response to these drugs. However, genetics is just one factor—diet, fasting habits, activity level, and overall health also play significant roles.

---

What are "receptor polymorphisms," and why do they matter?

A receptor is a lock on your cells; GLP-1 medication is the key. A polymorphism is a small, natural variation in a gene that can slightly change the lock's shape. Some people inherit GLP-1 or GIP receptor gene versions that make the lock easier or harder to open. According to a 2025 review in PubMed, these receptor gene variations explain why two people on identical medication and doses can experience noticeably different weight loss and blood sugar control outcomes.

---

What the Research shows:

• GLP-1 receptor gene variants are linked to differences in how strongly the body responds to GLP-1-based medications. Some variants may produce stronger appetite suppression, while others produce weaker effects, according to this receptor polymorphism review.

• GIP receptor gene variants are also relevant, particularly for dual-action medications like tirzepatide, which targets both GLP-1 and GIP receptors. Variations in the GIP receptor gene may similarly influence treatment benefit, per the same review.

• **This Research is still emerging. **** Genetic testing is not yet standard in GLP-1 prescribing, and no genetic test currently identifies which drug or dose is right for you. ** The science is promising but not yet ready for routine clinical use, as noted in the receptor polymorphism review. **

---

What this means for you:

• If your results feel slower than expected, genetics could be a factor—but so could fasting timing, food choices, sleep, and stress.
• Tracking your response over time provides your healthcare provider the real-world data needed to adjust your plan.
• Avoid comparing your results to others on the same medication. Biological individuality is real.

---

This section is for general information only and is not medical advice. Always consult a qualified healthcare professional before making changes to your medication or health plan.

FAQ

How do GLP-1 medications compare to other weight-loss drugs?

A 2025 systematic review and network meta-analysis published in the BMJ found that GLP-1 receptor agonists were among the more effective options for weight reduction in adults with overweight or obesity compared to several other drug classes. However, individual results varied (PMID 42419792). Always talk to a healthcare provider to understand which option, if any, may be appropriate for your situation. This is not medical advice.

Can GLP-1 medications reduce the risk of blood clots?

A multicenter U.S. cohort study found that tirzepatide was associated with a statistically significant reduced risk of pulmonary embolism and deep vein thrombosis compared to certain comparator treatments (PMID 42460324). These are observational findings and do not prove cause and effect. Speak with your doctor about your personal cardiovascular risk factors.

Do GLP-1 medications change what you want to eat?

The CRAVE study (PMID 42440974) observed changes in food cravings, dietary quality, body composition, and dietary intake among people using GLP-1 receptor agonists. Participants reported reductions in cravings for high-fat and sweet foods. Individual experiences can differ, and a registered dietitian can help you make the most of any dietary changes.

Are compounded GLP-1 medications safe to use?

Research published in JAMA Health Forum found that compounded GLP-1 receptor agonist products continued to be marketed in some states even after official drug shortage periods ended (PMID 42467450). Compounded medications are not FDA-approved and may vary in quality, concentration, and sterility. Consumers should consult a licensed healthcare provider before using any compounded version.

Are there special concerns for older adults taking GLP-1 medications?

A 2025 review in Advances in Therapy highlighted several considerations for older adults, including the risk of muscle mass loss alongside fat loss, potential interactions with other medications, and the importance of monitoring for dehydration and nutritional deficiencies (PMID 42423951). Older adults should work closely with their healthcare team to weigh benefits and risks.

Could my genetics affect how well a GLP-1 medication works for me?

Emerging Research published in the Journal of the Endocrine Society suggests that polymorphisms — natural variations — in GLP-1 and GIP receptor genes may influence how individuals respond to incretin-based therapies (PMID 42487666). This field is still developing, and genetic testing for this purpose is not yet standard clinical practice. Ask your provider about the latest guidance on personalized approaches.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs, and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.